Granules India Ltd (GRANULES) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Granules India, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. The company is among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain - from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs).

Over the years, the company has evolved itself from being an API manufacturer to a company that has a strong presence across the value chain. Cost efficiencies and continuous innovation continue to remain a core focus for the company that it strives to achieve through innovation at the development stage, ongoing continuous improvements and through various strategies across supply chain and manufacturing.

The company’s R&D capabilities come from the core value of ‘Innovation’, that drives the scientific teams to achieve efficient processes in API and robust Finished Dosage that meet global regulatory standards. It has emerged into a knowledge driven, R&D focused, multi-product organization, with inherent strength in efficient manufacturing of high-volume pharmaceutical products.

Business area of the company

Granules India is a vertically integrated pharmaceutical company with a presence across the entire value chain - from Active Pharmaceutical Ingredients (APIs) and Pharmaceutical Formulation Intermediates (PFIs) to Finished Dosages (FDs). The company’s differentiated business model, combining scale, cost leadership, and regulatory compliance, allows it to serve customers across several countries. The company’s manufacturing footprint spans India and the United States, supported by global R&D centres and a growing innovation pipeline.

Products of the company

• Active Pharmaceutical Ingredients
• Pharmaceutical Formulations Intermediates
• Finished Dosages

Milestones

• 1984: Formed Triton Laboratories to produce Paracetamol API at its Bonthapally facility in Hyderabad.
• 1990: Opened Triton’s second manufacturing facility at Jeedimetla to produce multiple APIs.
• 1991: Incorporated Granules India Private Limited.
• 1993: Established its first PFI facility at Jeedimetla.
• 1995: Became a listed company following an IPO at the Hyderabad Stock Exchange.
• 2003: Set up a new largevolume PFI facility in Gagillapur.
• 2003: Set up whollyowned subsidiary, Granules USA, for marketing in the US.
• 2005: Built a new Paracetamol plant in Bonthapally, Hyderabad.
• 2008: Entered the Finished Dosages segment.
• 2010: Received US FDA approval for its first Abbreviated New Drug Application (ANDA).
• 2013: Established API R&D facility in Pragathi Nagar.
• 2013: Acquired Auctus Pharma – an API manufacturing facility with regulatory approvals.
• 2014: Set up a whollyowned subsidiary in the US. Granules Pharmaceuticals began focusing on formulation R&D to forward integrate APIs.
• 2015: Laid the foundation for its Oncology API and OSD plant and a multiple product API plant in Visakhapatnam.
• 2019: Entered the frontend business for the sale of Rx Products in the US under the GPI label.
• 2021: Set up the largest single manufacturing site for a multiunit pellet system facility at Gagillapur.
• 2023: Set up GPAK, an around 80,000 sq. ft. packaging facility with four packaging suites and a warehousing facility.
• 2023: Established new purpose, mission and values.
• 2024: Granules Life Sciences (GLS), with a planned FD capacity of 10 bn dosages, successfully commenced operations.
• 2024: Granules CZRO pilot plant commenced operations.
• 2025: Successfully acquired Switzerland’s peptide CDMO firm Senn Chemicals AG.
• 2025: Inaugurated phase-II of GLS expanding dosage capacity to 10 billion dosages.